As cellular therapy products often cross international borders, it is important to be aware of applicable regulations in other regions. Products shipped across international borders must meet regulatory requirements of the competent authority of the exporting and importing country. Information on some non-U.S. competent authorities can be accessed via the links provided below. The information for each country is meant to serve as a resource, not a substitute for regulatory information or legal advice. Additionally, the information on this page is not updated in real-time, please contact the relevant competent authority to receive the most up-to-date information.
REGULATORY UPDATE: FDA Releases HCT/P Guidance Documents Related to Donor Eligibility
January 07, 2025
FDA Approves First MSC Therapy to Treat GvHD
January 02, 2025
BioBridge Global Launches BBG Advanced Therapies Subsidiary
January 02, 2025